In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments
Publication Date
March 15, 2023
Creator
Abstract
Background: Alzheimer’s disease (AD) is the most usual type of dementia, which often occurs in the late stage of life. As the population increases, the ageing problem has become more serious. Some researchers predicted that the number of AD patients would triple worldwide. Even though AD is a tough challenging disease, there are still no effective drugs or therapies that could modify and overcome it.
Objective: This report illustrates the evaluation of a new inhibitor compound 19n (AChE + metal) and methylprednisolone (MP) on An acute Aβ toxic mouse model, to prove whether the tested compounds have anti-AD efficacy in vivo. Design and methods: An acute Aβ toxic mouse model was established and the short-term evaluation Y maze and long-term evaluation Morris water maze were applied to test whether the cognitive impairment was improved by 19n and MP. After testing, the brain samples were collected for measuring the levels of cytokines and inflammatory factors.
Results: The results of behavioural evaluation demonstrated that after both 19n and MP were treated, the time consumption of finding the hidden platform was decreased and the proportion of time spent in the quadrant containing the platform was elevated. Besides, no toxicity was observed in both two compounds at the described dosage.
Conclusion: Both 19n and MP could alleviate Aβ-induced cognitive decline.
Item Type
ethesis
Thesis Type
MRes
Supervisors
Subjects (LC)
Associated Schools / Departments
School of Pharmacy (UK)
eprints ID
72113
UoN Repository URI
Except where otherwise noted, this item's license is described as
File(s)![Thumbnail Image]()
Name
zhangbocheng 14331661 MRes.pdf
Type
Full-text
Description
Examined
Size
2.23 MB
Format
Adobe PDF
Checksum (MD5)
18597359e0913943d157aaa7ea77461a